BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, November 12, 2025
Home » Topics » Science

Science
Science RSS Feed RSS

Calling bias sinks CCR5 work but is 'likely unique' to variant

Oct. 15, 2019
By Nuala Moran
LONDON – A paper that raised concerns for the future health of Lulu and Nana, the world's first gene-edited babies, has been fully retracted at the request of the authors, after they failed to identify a problem in data from the U.K. Biobank on which their analysis was based. The study published in Nature Medicine in June, concluded the edits the twin girls are purported to have in their CCR5 chemokine receptor gene is associated with a 21% increase in mortality in middle and old age.
Read More

Harvard researchers test in vivo, fluorescent, synthetic biology microbiome tool

Oct. 14, 2019
By Stacy Lawrence
Synthetic biology is seeing rapid advances, but the medical applications have thus far remained largely elusive. But now researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) have developed a tool that can track specific populations of bacteria in the gut of living organisms and document population changes over time.
Read More

New small-molecule inhibitors block apoptosis in mice

Oct. 14, 2019
By John Fox
Australian researchers have developed the first potent new small-molecule inhibitors capable of blocking the activation of apoptotic cell death before it causes damage to mitochondria, they reported in a study published in the Oct. 7, 2019, issue of Nature Chemical Biology. Those first-in-class inhibitors will be useful tools for evaluating the mechanisms underlying apoptosis, assessing the impact of the pharmacological blockade of apoptosis in experimental models and potentially have multiple clinical indications.
Read More

Bench Press: BioWorld looks at translational medicine

Oct. 14, 2019
By Anette Breindl
Researchers from Columbia University have demonstrated that correcting mutations in the schizophrenia risk gene SetD1 in adult mice reversed cognitive impairments, suggesting that, like a number of other brain disorders, schizophrenia's malfunctions begin in early development, but remain in place via ongoing active processes rather than reaching a point of no return. 
Read More

Harvard researchers test in vivo, fluorescent, synthetic biology microbiome tool with Dx potential

Oct. 14, 2019
By Stacy Lawrence
Synthetic biology is seeing rapid advances, but the medical applications have thus far remained largely elusive. But now researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) have developed a tool that can track specific populations of bacteria in the gut of living organisms and document population changes over time.
Read More

New small-molecule inhibitors block apoptosis in mice

Oct. 14, 2019
By John Fox
Australian researchers have developed the first potent new small-molecule inhibitors capable of blocking the activation of apoptotic cell death before it causes damage to mitochondria, they reported in a study published in the Oct. 7, 2019, issue of Nature Chemical Biology.
Read More

'Strength in numbers', 'it only takes one' both true for neoantigens

Oct. 11, 2019
By Anette Breindl
There's a yin and yang to neoantigens, Alberto Bardelli told the audience at the 2019 annual conference of the European Society of Medical Oncology (ESMO) in Barcelona, Spain, last month. They contribute to tumorigenesis, resistance and tumor heterogeneity. But they are also often specific to tumor cells but not normal cells and "some," he said, "are actionable targets."
Read More

‘Strength in numbers’, ‘it only takes one’ both true for neoantigens

Oct. 11, 2019
By Anette Breindl
There’s a yin and yang to neoantigens, Alberto Bardelli told the audience at the 2019 annual conference of the European Society of Medical Oncology (ESMO) in Barcelona, Spain, last month.
Read More

Calling bias sinks CCR5 work but is 'likely unique' to variant

Oct. 10, 2019
By Nuala Moran
LONDON – A paper that raised concerns for the future health of Lulu and Nana, the world's first gene edited babies, has been fully retracted at the request of the authors, after they failed to identify a problem in data from the U.K. Biobank on which their analysis was based.
Read More

Three win Nobel prize for their hypoxia work

Oct. 8, 2019
By Anette Breindl
William Kaelin, Peter Ratcliffe, and Gregg Semenza have jointly won the 2019 Nobel Prize "for their discoveries of how cells sense oxygen," the Nobel Assembly at Karolinska Institutet announced today.
Read More
Previous 1 2 … 178 179 180 181 182 183 184 185 186 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Nov. 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Nov. 12, 2025.
  • Female doctor and patient

    Could restricting diversity efforts stall women’s health research?

    BioWorld
    Recent progress in redressing the historical underfunding and neglect of women’s health could be undermined by the backlash against diversity, equity and...
  • Man falling asleep in car

    Alkermes’ alixorexton hits endpoints in narcolepsy phase II

    BioWorld
    Alkermes plc’s placebo-controlled phase II study of alixorexton in treating narcolepsy type 2 (NT2) hit its dual primary endpoints, producing statistically...
  • Pazdur ‘optimal fit’ to lead FDA’s CDER

    BioWorld
    In reaching within to name 26-year FDA veteran Richard Pazdur as the next CDER director, FDA Commissioner Marty Makary likely chose the best possible person to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing